Aeterna Zentaris to Present at NobleCon17
15 janv. 2021 08h05 HE
|
Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET – CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
05 janv. 2021 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
14 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h00 HE
|
Aeterna Zentaris Inc
- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
08 sept. 2020 08h05 HE
|
Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
03 août 2020 09h00 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
OmniPathology Releases New COVID-19 Testing for Greater Los Angeles
24 mars 2020 14h42 HE
|
OmniPathology
PASADENA, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- OmniPathology today announced the launch of its COVID-19 Lab Developed Test LDT. In response to the US Food and Drug Administration (FDA) policy...
BioPorto Appoints New President of BioPorto Diagnostics, Inc.
15 avr. 2019 09h00 HE
|
BioPorto A/S
Company Plans to Bring Novel Kidney Diagnostic to US Market Hellerup, Denmark, April 15, 2019 (GLOBE NEWSWIRE) -- Today, BioPorto A/S CPH: BIOPOR (“BioPorto”) announces the appointment of Amy...
DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease
16 mars 2015 08h02 HE
|
DiamiR
MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...
ARUP Laboratories Adds Prosigna to Its Test Menu
05 mars 2014 13h34 HE
|
ARUP Laboratories
SALT LAKE CITY, March 5, 2014 (GLOBE NEWSWIRE) -- ARUP Laboratories announced on Monday, March 3, that it has added the Prosigna Breast Cancer Prognostic Gene Signature assay to its comprehensive...